Equities research analysts forecast that Aptevo Therapeutics Inc (NASDAQ:APVO) will report $7.18 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aptevo Therapeutics’ earnings. The highest sales estimate is $7.50 million and the lowest is $6.86 million. Aptevo Therapeutics posted sales of $6.83 million during the same quarter last year, which suggests a positive year-over-year growth rate of 5.1%. The firm is scheduled to announce its next earnings report on Thursday, August 8th.

On average, analysts expect that Aptevo Therapeutics will report full year sales of $29.02 million for the current fiscal year, with estimates ranging from $28.02 million to $30.02 million. For the next financial year, analysts forecast that the company will report sales of $35.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Aptevo Therapeutics.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.44). The firm had revenue of $7.02 million during the quarter, compared to analysts’ expectations of $6.30 million. Aptevo Therapeutics had a negative return on equity of 119.17% and a negative net margin of 199.25%.

Several brokerages recently weighed in on APVO. ValuEngine lowered Aptevo Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Piper Jaffray Companies lowered their price objective on Aptevo Therapeutics from $8.50 to $4.00 and set an “overweight” rating for the company in a report on Wednesday, March 13th. Finally, Zacks Investment Research raised Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Thursday, March 14th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $7.88.

APVO stock traded down $0.03 during midday trading on Friday, hitting $0.75. 6,565 shares of the stock were exchanged, compared to its average volume of 549,952. The stock has a market cap of $33.57 million, a PE ratio of -0.32 and a beta of 2.64. Aptevo Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $6.35. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.66 and a current ratio of 2.76.

Several large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its position in Aptevo Therapeutics by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,442,049 shares of the biotechnology company’s stock worth $1,831,000 after purchasing an additional 16,482 shares during the period. Renaissance Technologies LLC lifted its position in Aptevo Therapeutics by 11.1% in the third quarter. Renaissance Technologies LLC now owns 1,277,100 shares of the biotechnology company’s stock worth $6,488,000 after purchasing an additional 127,700 shares during the period. Acadian Asset Management LLC lifted its position in Aptevo Therapeutics by 4.8% in the fourth quarter. Acadian Asset Management LLC now owns 462,824 shares of the biotechnology company’s stock worth $587,000 after purchasing an additional 21,059 shares during the period. Deutsche Bank AG lifted its position in Aptevo Therapeutics by 251.7% in the fourth quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock worth $419,000 after purchasing an additional 236,300 shares during the period. Finally, Clifford Swan Investment Counsel LLC acquired a new stake in Aptevo Therapeutics in the fourth quarter worth approximately $35,000. 17.08% of the stock is owned by institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Recommended Story: What is a put option?

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.